On June 22, 2025, Beta Bionics, Inc. reported positive data from 16,439 users of its iLet Bionic Pancreas, showing HbA1c improvement from an average of 8.9% to 7.3% over the first two years since its commercial launch. The data indicates over 84% of users met hypoglycemia goals.